Market Overview

Teva Says Omacetaxine Mepesuccinate Shows Activity in CML

Share:
Related TEVA
Teva Shareholders Shrug Off Latest Collaborative Research Agreement
Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.

Posted-In: News FDA

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters